Generated by AI
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing oncology therapies, with an emphasis on immuno-oncology and cancer-supportive care. The company’s core programs center on Plinabulin, a lead candidate being studied for use in non-small cell lung cancer and in the prevention of chemotherapy-induced neutropenia, a condition that can complicate cancer treatment. BeyondSpring also operates a TPD platform that supports the discovery and development of therapeutic agents and new chemical entities. Its work is directed at addressing unmet needs in cancer care through targeted drug development and clinical research. Headquartered in Florham Park, New Jersey, BeyondSpring Inc. plays a specialized role in the biotechnology market as a research-driven company advancing late-stage and early-stage therapeutic candidates.
Website100 Campus Drive
Florham Park, NJ, 07932
United States
The latest articles about BYSI.
Detailed price information for Beyondspring Inc (BYSI-Q) from The Globe and Mail including charting and trades.
BeyondSpring received FDA Fast Track designation for Plinabulin plus docetaxel in post-ICI non-squamous NSCLC and announced a strategic transaction designed to reduce the cash required to advance its global Phase 3 DUBLIN-4 trial toward a prespecified interim analysis. Key Investor TakeawaysBeyondSpring (NASDAQ:BYSI) received FDA Fast Track designation for Plinabulin plus docetaxel in advanced or metastatic non-squamous NSCLC following prior anti-PD-(L)1 therapy and platinum chemotherapy.
Summary of Sep 29's posts. Generated by AI.
Summary of Aug 13's posts. Generated by AI.
Summary of Dec 2's posts. Generated by AI.
Summary of Sep 29's posts. Generated by AI.
Investors talking about BYSI also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.